NCT05264623进行中（未招募）不适用
A Study to Investigate the Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 140
- 试验地点
- 16
- 主要终点
- The percentage of eyes with Uncorrected Distance Visual Acuity (UDVA) of 20/40 or better at the time of refractive stability
研究概览
简要总结
This will be a multicenter, prospective, open label, non-randomized, single arm 12 month study, evaluating the safety and effectiveness of the TECHNOLAS TENEO 317 Model 2 (Software version "1.28 US") excimer laser when used in LASIK surgery to treat hyperopia with or without hyperopic astigmatism. Both eyes of a subject may be enrolled so long as both eyes meet all inclusion/exclusion requirements. Analysis of the primary effectiveness endpoint will be completed at refractive stability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects 22 years of age or older at the time of the pre-operative examination.
- •Manifest, distance corrected visual acuity (CDVA) 20/25 (logMAR 0.10) or better in an operative eye
- •Pre-operative refractive error of hyperopia with spherical component of 0.00 D to +4.00 D with or without cylinder up to +2.00 D, with MRSE of ≥ 0.375 D and ≤ +5.00 D based on the manifest refraction in thestudy eye(s). This would exclude eyes with cylinder-only corrections < +0.75D and sphere-only corrections < +0.375D)
- •Difficulty maintaining uncorrected distance visual acuity (UDVA) of 20/40 or better, as evidenced by need for constant contact lens or spectacle wear.
- •Difference between manifest refractive and cycloplegic spherical equivalent ≤ 0.75 D, difference between manifest and cycloplegic cylinder ≤ ± 0.50 D and difference between manifest and cycloplegic cylinder axis ≤ ± 15 degrees.
- •Stable refraction (i.e., a change of ≤ ± 0.50 D in MRSE) for a minimum of 12 months prior to surgery, as verified by consecutive refractions, medical records, or prescription history.
- •Agree to discontinue use of contact lenses for at least 2 weeks (for rigid or toric lenses) or 3 days (for soft contact lenses) prior to the first refraction used to establish stability and through the day of surgery.
- •All contact lens wearers must demonstrate a stable refraction in an eye to be treated, as follows: two consecutive examinations at least 1 week apart within ± 0.50 D manifest refractive spherical equivalent and within ± 15 degrees cylinder axis.
- •Agree to emmetropia correction for each treated eye.
- •Anticipated postoperative stromal bed thickness of at least 250 microns.
- •Can lie flat without difficulty.
- •Willing and able to read, understand, and sign a written informed consent form (ICF).
- •Willing and able to comply with the schedule for all post-surgery follow-up visits.
排除标准
- •Acute or chronic disease or illness that would increase operative risk or confound the results of the study (e.g., dry eye disease, cataract, glaucoma, immuno-compromised, rheumatoid arthritis, clinically significant atopic disease, acne rosacea, autoimmune disease, endocrine disorders, lupus, systemic connective tissue disease, diabetes, or severe atopic disease).
- •Use of medications by any administration route that may increase risk to the subject or may confound the outcome of the study, including those known to affect wound healing (e.g., systemic corticosteroids, antimetabolites).
- •Ocular conditions, other than hyperopia with or without astigmatism that may predispose the subject to future complications including but not limited to:
- •Evidence or history of retinal vascular disease
- •Evidence or history of active or inactive corneal disease or infection (e.g., recurrent corneal erosion syndrome, herpes simplex or herpes zoster keratitis) in either eye.
- •Evidence or history of glaucoma or glaucoma suspect (IOP > 24mmHg) by exam findings and/or family history
- •Previous intraocular or corneal surgery in an eye considered for eligibility that might confound the outcome of the study or increase the risk to the subject.
- •An increased risk for developing strabismus post-treatment or an ocular muscle disorder (e.g., strabismus or nystagmus) affecting fixation.
- •Known sensitivity to any study medications (e.g., used during LASIK procedure and postoperative care).
- •Have central corneal scars affecting visual acuity.
- •Have mixed astigmatism.
- •Presence of keratoconus, keratoconus suspect, subclinical or forme fruste keratoconus, corneal dystrophy, or other corneal irregularity (e.g., irregular astigmatism) or abnormal corneal topography
- •Presence of visually significant or progressive cataract in an eye considered for eligibility.
- •Actively taking medications contraindicated with LASIK such as isotretinoin (Accutane) or amiodarone hydrochloride (Cordarone).
- •Have a cardiac pacemaker, implanted defibrillator, or other implanted electronic device.
- •Pregnant, lactating, or subjects who plan to become pregnant during the course of the study.
- •Are participating in any other trial within 30 days of screening or during this clinical trial.
- •Eyes with mesopic pupil size > 7.0 mm.
- •Have a Schirmer's pre-operative test without anesthesia < 4 mm after 5 minutes
研究组 & 干预措施
TENEO 317 Model 2 excimer laser
Experimental
干预措施: TENEO 317 Model 2 excimer laser (Device)
结局指标
主要结局
The percentage of eyes with Uncorrected Distance Visual Acuity (UDVA) of 20/40 or better at the time of refractive stability
时间窗: Up to 12 months
The percentage of eyes with Manifest Refractive Spherical Equivalent (MRSE) within 0.50 Diopter of intended correction at the time of refractive stability
时间窗: Up to 12 months
The percentage of eyes with Manifest Refractive Spherical Equivalent (MRSE) within 1.00 Diopter of intended correction at the time of refractive stability
时间窗: Up to 12 months
次要结局
未报告次要终点
研究者
研究点 (16)
Loading locations...
相似试验
已完成
不适用
An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second RelapseGlioblastoma MultiformeNCT01618747Hoffmann-La Roche20
Unknown
早期 1 期
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple MyelomaMultiple MyelomaNCT04236011Shanghai Changzheng Hospital15
进行中（未招募）
不适用
PREEMIE: Study for Treatment of PDA in Premature InfantsPatent Ductus Arteriosus (PDA)NCT06587282Merit Medical Systems, Inc.55
终止
不适用
Severe OSA Study (SOS)Obstructive Sleep ApneaSleep ApneaNCT05445869ProSomnus Sleep Technologies35
Unknown
早期 1 期
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple MyelomaMultiple MyelomaNCT04617704Shanghai Changzheng Hospital15